Can I Take St. John's Wort with Retatrutide?

What Retatrutide Is and How It Works

Retatrutide is an investigational triple-hormone receptor agonist that activates GLP-1, GIP, and glucagon receptors simultaneously. It is administered as a once-weekly subcutaneous injection. In the phase 2 trial published in the New England Journal of Medicine (N=338), participants receiving the highest dose of retatrutide (12 mg weekly) lost a mean of 24.2% of body weight at 48 weeks, compared with 2.1% in the placebo group [1].

Metabolic Pathway

Like other peptide-based GLP-1 receptor agonists (semaglutide, tirzepatide), retatrutide is primarily degraded through proteolytic cleavage and not through cytochrome P450 enzymes in the liver [2]. This distinction matters. Drugs that rely on CYP3A4 for clearance (cyclosporine, certain statins, hormonal contraceptives) are vulnerable to enzyme inducers or inhibitors. Peptides that skip the CYP pathway are not.

Why This Matters for Supplement Interactions

The practical result: a supplement that speeds up CYP3A4 activity would not be expected to change how fast your body breaks down retatrutide itself. The interaction risk with St. John's Wort is indirect, not direct.

How St. John's Wort Affects Drug Metabolism

St. John's Wort has earned a reputation as one of the most clinically significant herbal products in terms of drug interactions. The active compound hyperforin binds to the pregnane X receptor (PXR) and upregulates expression of CYP3A4, CYP2C9, CYP1A2, and the drug transporter P-glycoprotein (P-gp) [3].

The CYP3A4 Induction Problem

CYP3A4 metabolizes roughly 50% of all prescription drugs. When St. John's Wort ramps up CYP3A4 activity, it accelerates the clearance of those drugs, dropping their blood levels below therapeutic thresholds. A systematic review by Borrelli and Izzo (2009) cataloged clinically documented interactions with oral contraceptives, cyclosporine, warfarin, digoxin, HIV protease inhibitors, and multiple antidepressants [3].

P-glycoprotein Induction

St. John's Wort also upregulates P-gp in the intestinal wall. This transporter pumps certain drugs back into the gut lumen before they can be absorbed. The effect compounds the CYP3A4 induction: drugs get broken down faster AND absorbed less efficiently.

Variability Between Products

Hyperforin content drives the magnitude of enzyme induction. A 2014 analysis found hyperforin concentrations ranged from 0.01% to 5.7% across commercial St. John's Wort products in the United States [4]. Products labeled "low hyperforin" may cause less enzyme induction, but there is no standardized threshold that guarantees safety.

Is There a Direct Pharmacokinetic Interaction?

Based on what is known about retatrutide's metabolic fate, a direct pharmacokinetic interaction with St. John's Wort is unlikely. Here is the reasoning.

Peptides Bypass CYP Metabolism

Retatrutide is a 39-amino-acid peptide. The FDA's 2020 guidance on drug interaction studies for therapeutic proteins states that "therapeutic protein products are unlikely to be involved in CYP-mediated drug interactions" because they are catabolized by ubiquitous proteolytic enzymes rather than CYP isoforms [5]. Semaglutide's prescribing information confirms this principle: Novo Nordisk conducted in vitro CYP interaction studies and found no clinically relevant effects [6].

No Direct Data Exist

No published study has tested the combination of retatrutide and St. John's Wort in humans or in vitro. Eli Lilly's phase 2 and phase 3 trial protocols for retatrutide have not included St. John's Wort interaction arms. The absence of data does not guarantee safety, but the pharmacological reasoning supports a low probability of direct interaction.

A Decision Framework for Your Prescriber

The question is not just whether St. John's Wort changes retatrutide levels. It is whether St. John's Wort changes the levels of everything else you are taking. Patients prescribed retatrutide for obesity frequently also take metformin, atorvastatin, lisinopril, levothyroxine, or oral contraceptives. St. John's Wort can reduce atorvastatin AUC by up to 50% [7]. It can cause breakthrough bleeding and contraceptive failure with combined oral contraceptives [3]. Your prescriber needs a complete medication and supplement list to assess the full interaction picture.

Pharmacodynamic Concerns: Mood, Appetite, and Serotonin

Even without a pharmacokinetic clash, combining St. John's Wort and retatrutide raises pharmacodynamic questions worth examining.

Appetite and Mood Overlap

Patients often take St. John's Wort for mild to moderate depression. Obesity and depression are bidirectionally linked: a meta-analysis by Luppino et al. (2010, N=58,745 across 15 studies) found that obese individuals had a 55% increased risk of developing depression, while depressed individuals had a 58% increased risk of becoming obese [8]. Patients seeking retatrutide for weight management may be taking St. John's Wort precisely because mood and weight are intertwined in their clinical picture.

Serotonin Syndrome Risk with Co-prescribed Antidepressants

St. John's Wort inhibits serotonin reuptake. If a patient is also taking an SSRI or SNRI (commonly prescribed in the obesity population), combining it with St. John's Wort increases serotonin syndrome risk. The FDA issued a 2014 safety communication warning about this combination [9]. GLP-1 receptor agonists themselves do not raise serotonin, but nausea from retatrutide could mask early serotonin syndrome symptoms (nausea, diarrhea, agitation), delaying recognition.

GI Effects

Both St. John's Wort and GLP-1 receptor agonists can cause gastrointestinal side effects. In the retatrutide phase 2 trial, nausea occurred in 22.6% to 45.5% of participants across dose groups [1]. St. John's Wort causes GI upset in approximately 5% of users according to Cochrane review data [10]. Additive GI discomfort is a realistic possibility, not a theoretical one.

What the Guidelines and Databases Say

No major clinical guideline addresses the specific retatrutide + St. John's Wort pair, because retatrutide has not yet received FDA approval. The relevant guidance comes from broader interaction databases and analogous drug class data.

Natural Medicines Database

The Natural Medicines Comprehensive Database classifies St. John's Wort interactions by severity. It assigns "major" interaction ratings to any drug primarily metabolized by CYP3A4 [4]. Peptide therapeutics are not flagged in this category because they do not undergo CYP metabolism.

Endocrine Society and AGA Guidelines

The 2023 American Gastroenterological Association (AGA) clinical practice guideline on pharmacological management of obesity recommends that clinicians "review all concurrent medications, including over-the-counter and herbal products, for potential interactions" when prescribing anti-obesity medications [11]. This is a broad recommendation, not specific to St. John's Wort, but it applies directly.

FDA Labeling Precedent from Similar Peptides

Tirzepatide (Mounjaro/Zepbound) labeling notes that "no clinically meaningful pharmacokinetic drug interactions were identified" in formal interaction studies with CYP substrates [12]. While tirzepatide does transiently slow gastric emptying (which can affect absorption timing of oral drugs), the CYP-mediated pathway is not a concern. The same reasoning applies to retatrutide based on shared peptide pharmacology.

If You Are Already Taking Both

Some patients reading this article are already combining St. John's Wort with retatrutide obtained through a clinical trial or early access. Here is what to do.

Do Not Stop St. John's Wort Abruptly

If you have been taking St. John's Wort regularly for weeks, your CYP3A4 activity is upregulated. Stopping suddenly means CYP3A4 activity will return to baseline over 1 to 2 weeks. During this de-induction window, blood levels of any CYP3A4-substrate drug you take will rise. For drugs with narrow therapeutic indices (warfarin, cyclosporine), this rebound can be dangerous [3]. Taper under medical supervision.

Tell Your Prescriber Everything

Bring the bottle. Include the brand name, dose, and hyperforin content if listed. Your prescriber needs this to assess whether any of your other medications are affected.

Monitor for GI Side Effects

Track nausea, diarrhea, and abdominal discomfort in a symptom diary during the first 4 to 6 weeks. If GI symptoms worsen after adding either agent, report it at your next visit rather than waiting.

Request Mood Monitoring

If St. John's Wort is managing depressive symptoms, your clinician should monitor whether retatrutide-related weight loss affects your mood trajectory. Weight loss itself can improve depressive symptoms in some patients [8], which may reduce the need for St. John's Wort over time.

Safer Alternatives to St. John's Wort for Mood Support

If your prescriber recommends discontinuing St. John's Wort due to polypharmacy concerns, several alternatives exist with fewer drug interaction liabilities.

Prescription Options

SSRIs like sertraline and escitalopram do not induce CYP3A4. Bupropion, which is FDA-approved for both depression and (in combination with naltrexone) for weight management, offers dual benefit in patients with comorbid obesity and depression. However, bupropion's own CYP2B6 metabolism means it has its own interaction profile to review.

Non-pharmacological Approaches

Cognitive behavioral therapy (CBT) has a strong evidence base for mild to moderate depression and carries zero drug interaction risk. A Cochrane review of 131 trials found CBT was more effective than no treatment, waitlist, or treatment-as-usual controls for major depression [13]. Exercise, which complements GLP-1 agonist therapy for weight management, also has antidepressant effects supported by meta-analytic data.

Timeline: When Retatrutide Interaction Data May Arrive

Retatrutide is in phase 3 development. Eli Lilly's TRIUMPH program includes multiple phase 3 trials evaluating retatrutide for obesity and type 2 diabetes. Formal drug interaction studies are typically completed before or during phase 3 and included in the eventual prescribing information. As of mid-2026, no formal interaction study results for retatrutide have been published, though the FDA will require this data before approval.

The Endocrine Society's 2024 clinical practice guideline on pharmacological treatment of obesity recommended that prescribers "anticipate a need for updated interaction screening as new anti-obesity agents receive approval" [14]. Once retatrutide's full prescribing information is available, specific supplement interaction guidance should follow.

Patients enrolled in retatrutide clinical trials should report all supplement use to study investigators, as unreported herbal product use can confound safety and efficacy data.